Use of savolitinib as neoadjuvant therapy for non–small cell lung cancer patient with MET exon 14 skipping alterations: A case report

Savolitinib is a tyrosine kinase inhibitor being developed for the treatment of metastatic non–small cell lung cancer (NSCLC) with mesenchymal–epithelial transition (MET) factor exon 14 skipping alterations. However, the role of savolitinib in neoadjuvant therapy for lung cancer remains unclear. Here, we present a case of a 65-year-old woman diagnosed with stage IIIA (cT2bN2M0, eighth TNM stage) upper right lung adenocarcinoma harboring MET exon 14 skipping alterations. After 4 weeks of therapy, a partial response was achieved with neoadjuvant savolitinib, and significant shrinkage in tumor and lymph nodes was observed. We also measured the immune microenvironment of the primary tumor pre- and posttreatment with savolitinib.

[1]  A. Markham.  Savolitinib: First Approval , 2021, Drugs.

[2]  Z. Lou,et al.  MET amplification attenuates lung tumor response to immunotherapy by inhibiting STING. , 2021, Cancer discovery.

[3]  Shi-yue Li,et al.  Case Report: Neoadjuvant and Adjuvant Crizotinib Targeted Therapy in Stage IIIA-N2 ALK-Positive Non-Small-Cell Lung Cancer , 2021, Frontiers in Oncology.

[4]  W. Liang,et al.  Non-small cell lung cancer with MET exon 14 skipping alteration responding to immunotherapy: a case report , 2021, Annals of translational medicine.

[5]  Jianjun Zhang,et al.  Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer , 2021, Therapeutic advances in medical oncology.

[6]  E. Longchampt,et al.  Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14-skipping mutation: A series of 6 cases. , 2020, Lung cancer.

[7]  Ying Cheng,et al.  Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  C. Blakely,et al.  Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation , 2019, Clinical lung cancer.

[9]  A. Drilon,et al.  PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  P. Stephens,et al.  Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  R. Doebele,et al.  Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance. , 2016, Clinical lung cancer.

[12]  N. Schultz,et al.  Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. , 2015, Cancer discovery.

[13]  Ravi Salgia,et al.  Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. , 2005, Cancer research.

[14]  R. Salgia,et al.  c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. , 2003, Cancer research.

[15]  D. C. Henckel,et al.  Case report. , 1995, Journal.